Novo Holdings Reports Strong Momentum in Asia Across Healthcare and Planetary Health in 2024
SINGAPORE, June 18, 2025 /PRNewswire/ -- Novo Holdings today released its Asia Investments Year in Review 2024, highlighting a year of strategic growth and purpose-driven investing across healthcare, life sciences, and planetary health in key Asian markets. The report underscores Novo Holdings' commitment to building long-term partnerships that deliver both financial returns and societal impact.
Now in its fifth year, the Novo Holdings Asia platform continues to strengthen its footprint across the region, with teams based in Singapore, Shanghai, and an upcoming office in Mumbai.
Highlights from 2024 include:
Largest-ever Asia investment in India's Manipal Hospitals, a leading provider of high-quality, affordable healthcare
First Planetary Health investment in Asia, backing AgNext Technologies in India to enhance food quality and safety using AI
Enhanced presence in China with the opening of an expanded office in Shanghai, reaffirming long-term regional commitment
Continued support for digital health innovators, including follow-on investments in Qure.ai and MedGenome
The Year in Review also reflects positive progress across Novo Holdings' Asia portfolio, with key portfolio milestones including FDA clearance for Qure.ai's lung nodule detection tool, strategic acquisitions by Manipal Hospitals and Medi Assist, and the launch of Doctor Anywhere's integrated MedSuites facility in Singapore.
Amit Kakar, Managing Partner and Head of Asia at Novo Holdings, said:"In 2024, we advanced our mission of investing in innovation that improves lives, through strengthening healthcare systems, advancing AI in diagnostics, and enabling more sustainable food production. These investments reflect the scale and urgency of the challenges Asia faces, and the opportunity to be part of transformative solutions.
Looking ahead, we are excited to continue expanding our regional platform, deepening our partnerships, and identifying new ways to drive impact at the intersection of health, science, and sustainability."
Read the full review at: https://novoholdings.dk/news/novo-holdings-reports-strong-momentum-in-asia-across-healthcare-and-planetary-health-in-2024
About Novo HoldingsNovo Holdings is a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (formerly Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure, and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health, and Principal Investments teams, Novo Holdings invests in life sciences companies at all stages of development. As of year-end 2024, Novo Holdings had total assets of EUR 142 billion.www.novoholdings.dk
Further information:
Paul Ewing-ChowHead of Corporate Affairs Asiapec@novo.dk
View original content:https://www.prnewswire.com/apac/news-releases/novo-holdings-reports-strong-momentum-in-asia-across-healthcare-and-planetary-health-in-2024-302484881.html
SOURCE Novo Holdings
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
China's soymeal glut raises demand doubts ahead of US soybean export season
By Ella Cao and Naveen Thukral BEIJING/SINGAPORE (Reuters) -China's appetite for soybeans is likely to weaken during the peak U.S. marketing season later this year, as record imports earlier in 2025 and tepid demand from animal feed producers have pushed up soymeal inventories at home, trade sources said. The world's biggest soybean importer has yet to book U.S. cargoes for the fourth quarter, with traders closely monitoring talks in Stockholm aimed at resolving longstanding economic disputes at the centre of the U.S.-China trade war. A slowdown in Chinese demand could pressure Chicago soybean futures, which are already down for a second consecutive week on expectations of a bumper U.S. harvest. [GRA/] China's soymeal futures fell for a fourth straight session on Tuesday amid ample supplies. In the physical market, spot soymeal in north China was quoted at 2,925 yuan ($408) per metric ton, down 6.5% from 3,130 yuan a year ago, said Wang Wenshen, an analyst at Shandong province-based consultancy Sublime China Information. "If third-quarter prices stay weak and crushers face losses, fourth-quarter soybean purchases may fall short of expectations," Wang said. The last quarter of the year is typically the main U.S. soybean marketing season. China's overall soybean imports hit a record high in May and their second-highest level in June, boosting oilseed processing and leading to a buildup in soymeal inventories, traders said. CRUSHER SHUTDOWNS The surplus is straining China's crushing plants, with some already shutting down due to storage constraints. "Small-scale shutdowns have already begun at crushing plants in regions like south China primarily because soybean meal has accumulated with no room for more stock," said a Shanghai-based trader, adding that a broader suspension was "highly likely". Crush margins in Rizhao, China's main processing hub, have been negative since mid-May. The glut has been worsened by weak demand from animal feed producers amid sluggish meat consumption in the world's top pork market. Crushers will face "huge soymeal stock pressure" over the next one to two months, said Cheang Kang Wei, vice president at StoneX in Singapore. Authorities have pledged to cut breeding sow numbers, curb new capacity, and reduce soymeal use in feed to stabilise meat prices after steep declines this year, measures analysts say will further limit soymeal consumption. China's purchases of Argentine soymeal, amid high tariffs of U.S. beans, in the last few weeks are likely to add to the glut. "Even with such big supply of soymeal in the local market, it is profitable to import meal from Argentina," said a Singapore-based trader at an international trading company. "This will only add to the stocks of soymeal." A trade deal with Washington could shift buying patterns. "If a trade deal is reached, Chinese buyers could resume U.S. purchases for the fourth quarter, as prices are favourable without tariffs," said Johnny Xiang, founder of Beijing-based AgRadar Consulting. ($1 = 7.1767 Chinese yuan)
Yahoo
12 minutes ago
- Yahoo
Amplitude Surgical
VALENCE, France, July 29, 2025--(BUSINESS WIRE)--Regulatory News: Amplitude Surgical company has requested Euronext to suspend the listing of its shares (ISIN: FR0012789667, Ticker: AMPLI, eligible PEA-PME) on Euronext market with effect as from the publication of this press release and pending publication of a further press release. About Amplitude Surgical Founded in 1997 in Valence, Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main pathologies affecting the hip and knee. Amplitude Surgical develops, in close collaboration with surgeons, a number of high value-added innovations to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is expanding internationally through its subsidiaries and a network of exclusive agents and distributors in more than 30 countries. As of June 30, 2025, Amplitude Surgical employed 429 people and generated revenue of nearly €111 million. View source version on Contacts Amplitude Surgical Chief Financial Officer Dimitri Borchtch finances@ +33 (0)4 75 41 87 41 NewCap Investor Relations Thomas Grojean amplitude@ +33 (0)1 44 71 94 94 NewCap Media Relations Nicolas Merigeau amplitude@ +33 (0)1 44 71 94 98 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
14 minutes ago
- Wall Street Journal
A Buddhist Monk's Alleged Indulgence in Money and Sex Transfixes China
Shi Yongxin rode in luxury cars, traveled the world to meet the rich and powerful, and presided over a globe-spanning business empire. He's also a monk and the abbot of China's Shaolin Temple—perhaps the world's most famous Buddhist monastery, founded more than 1,500 years ago and renowned today as the birthplace of Zen Buddhism and a cradle of Chinese martial arts.
